These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 19224111)

  • 1. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.
    Diniz BS; Pinto JA; Gonzaga ML; Guimarães FM; Gattaz WF; Forlenza OV
    Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):248-56. PubMed ID: 19224111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials.
    Raschetti R; Albanese E; Vanacore N; Maggini M
    PLoS Med; 2007 Nov; 4(11):e338. PubMed ID: 18044984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholinesterase inhibitors in mild cognitive impairment: a meta-analysis of randomized controlled trials.
    Sobów T; Kłoszewska I
    Neurol Neurochir Pol; 2007; 41(1):13-21. PubMed ID: 17330176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginkgo biloba Extract (EGb761), Cholinesterase Inhibitors, and Memantine for the Treatment of Mild-to-Moderate Alzheimer's Disease: A Network Meta-Analysis.
    Thancharoen O; Limwattananon C; Waleekhachonloet O; Rattanachotphanit T; Limwattananon P; Limpawattana P
    Drugs Aging; 2019 May; 36(5):435-452. PubMed ID: 30937879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
    Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R
    Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
    Han JY; Besser LM; Xiong C; Kukull WA; Morris JC
    Alzheimer Dis Assoc Disord; 2019; 33(2):87-94. PubMed ID: 30633043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in cognitive function according to cholinesterase inhibitor use and amyloid PET positivity in patients with mild cognitive impairment.
    Pyun JM; Ryoo N; Park YH; Kim S
    Alzheimers Res Ther; 2021 Jan; 13(1):10. PubMed ID: 33402198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
    Lanctôt KL; Herrmann N; Yau KK; Khan LR; Liu BA; LouLou MM; Einarson TR
    CMAJ; 2003 Sep; 169(6):557-64. PubMed ID: 12975222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
    O'Regan J; Lanctôt KL; Mazereeuw G; Herrmann N
    J Clin Psychiatry; 2015 Nov; 76(11):e1424-31. PubMed ID: 26646039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early- versus late-onset Alzheimer's disease in clinical practice: cognitive and global outcomes over 3 years.
    Wattmo C; Wallin ÅK
    Alzheimers Res Ther; 2017 Aug; 9(1):70. PubMed ID: 28859660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychosocial interventions for Alzheimer's disease cognitive symptoms: a Bayesian network meta-analysis.
    Duan Y; Lu L; Chen J; Wu C; Liang J; Zheng Y; Wu J; Rong P; Tang C
    BMC Geriatr; 2018 Aug; 18(1):175. PubMed ID: 30086714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors are associated with reduced mortality in patients with Alzheimer's disease and previous myocardial infarction.
    Shahim B; Xu H; Haugaa K; Zetterberg H; Jurga J; Religa D; Eriksdotter M
    Eur Heart J Cardiovasc Pharmacother; 2024 Feb; 10(2):128-136. PubMed ID: 38224338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Huperzine A for Alzheimer's disease.
    Li J; Wu HM; Zhou RL; Liu GJ; Dong BR
    Cochrane Database Syst Rev; 2008 Apr; (2):CD005592. PubMed ID: 18425924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metrifonate for Alzheimer's disease.
    López-Arrieta JM; Schneider L
    Cochrane Database Syst Rev; 2006 Apr; (2):CD003155. PubMed ID: 16625573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil for mild and moderate Alzheimer's disease.
    Birks J S; Melzer D
    Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contemporary issues in the treatment of Alzheimer's disease: tangible benefits of current therapies.
    Tariot PN
    J Clin Psychiatry; 2006; 67 Suppl 3():15-22; quiz 23. PubMed ID: 16649847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.